{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T12:26:11Z","timestamp":1791116771236,"version":"4.1.0"},"reference-count":199,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"CSIR SIP-08"},{"name":"NIA"},{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"crossref","award":["3094"],"award-info":[{"award-number":["3094"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular and Cellular Neuroscience"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.mcn.2012.11.011","type":"journal-article","created":{"date-parts":[[2012,12,5]],"date-time":"2012-12-05T11:29:59Z","timestamp":1354706999000},"page":"101-114","source":"Crossref","is-referenced-by-count":124,"special_numbering":"C","title":["Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases"],"prefix":"10.1016","volume":"55","author":[{"given":"Rajnish K.","family":"Chaturvedi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Flint","family":"Beal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcn.2012.11.011_bb0005","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/ana.20624","article-title":"Mitochondria take center stage in aging and neurodegeneration","volume":"58","author":"Beal","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.mcn.2012.11.011_bb0010","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nature05292","article-title":"Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases","volume":"443","author":"Lin","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.mcn.2012.11.011_bb0015","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1126\/science.6823561","article-title":"Chronic parkinsonism in humans due to a product of meperidine-analog synthesis","volume":"219","author":"Langston","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.mcn.2012.11.011_bb0020","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1056\/NEJM198505303122203","article-title":"The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)","volume":"312","author":"Burns","year":"1985","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mcn.2012.11.011_bb0025","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1196\/annals.1427.027","article-title":"Mitochondrial approaches for neuroprotection","volume":"1147","author":"Chaturvedi","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.mcn.2012.11.011_bb0030","doi-asserted-by":"crossref","first-page":"42026","DOI":"10.1074\/jbc.M508628200","article-title":"Rotenone model of Parkinson disease: multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication","volume":"280","author":"Panov","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mcn.2012.11.011_bb0035","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1750-1326-3-21","article-title":"Chronic, low-dose rotenone reproduces Lewy neurites found in early stages of Parkinson's disease, reduces mitochondrial movement and slowly kills differentiated SH-SY5Y neural cells","volume":"3","author":"Borland","year":"2008","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.mcn.2012.11.011_bb0040","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.2741\/2128","article-title":"Pesticides and impairment of mitochondrial function in relation with the parkinsonian syndrome","volume":"12","author":"Gomez","year":"2007","journal-title":"Front. Biosci."},{"key":"10.1016\/j.mcn.2012.11.011_bb0045","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/ana.410440207","article-title":"Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease","volume":"44","author":"Gu","year":"1998","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.mcn.2012.11.011_bb0050","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.expneurol.2009.09.025","article-title":"Cybrid models of Parkinson's disease show variable mitochondrial biogenesis and genotype-respiration relationships","volume":"220","author":"Keeney","year":"2009","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.mcn.2012.11.011_bb0055","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.expneurol.2009.03.016","article-title":"The cybrid model of sporadic Parkinson's disease","volume":"218","author":"Trimmer","year":"2009","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.mcn.2012.11.011_bb0060","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1172\/JCI43871","article-title":"Direct regulation of complex I by mitochondrial MEF2D is disrupted in a mouse model of Parkinson disease and in human patients","volume":"121","author":"She","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.mcn.2012.11.011_bb0065","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bbadis.2008.09.014","article-title":"Relationships among molecular genetic and respiratory properties of Parkinson's disease cybrid cells show similarities to Parkinson's brain tissues","volume":"1792","author":"Borland","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.mcn.2012.11.011_bb0070","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1471-4159.2010.06631.x","article-title":"Mitochondrial respiration and respiration-associated proteins in cell lines created through Parkinson's subject mitochondrial transfer","volume":"113","author":"Esteves","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.mcn.2012.11.011_bb0075","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1089\/hum.2009.023","article-title":"Mitochondrial gene therapy augments mitochondrial physiology in a Parkinson's disease cell model","volume":"20","author":"Keeney","year":"2009","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.mcn.2012.11.011_bb0080","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0197-4580(03)00037-X","article-title":"Somatic mitochondrial DNA mutations in cortex and substantia nigra in aging and Parkinson's disease","volume":"25","author":"Simon","year":"2004","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.mcn.2012.11.011_bb0085","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0169-328X(94)00209-W","article-title":"Point mutations of mitochondrial genome in Parkinson's disease","volume":"28","author":"Ikebe","year":"1995","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.mcn.2012.11.011_bb0090","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/jnen\/61.7.634","article-title":"Mitochondrial DNA deletions\/rearrangements in Parkinson disease and related neurodegenerative disorders","volume":"61","author":"Gu","year":"2002","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.mcn.2012.11.011_bb0095","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1212\/WNL.53.8.1787","article-title":"Familial multisystem degeneration with parkinsonism associated with the 11778 mitochondrial DNA mutation","volume":"53","author":"Simon","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.mcn.2012.11.011_bb0100","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/ng1778","article-title":"Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons","volume":"38","author":"Kraytsberg","year":"2006","journal-title":"Nat. Genet."},{"key":"10.1016\/j.mcn.2012.11.011_bb0105","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1093\/hmg\/ddq370","article-title":"Dissecting the role of the mitochondrial chaperone mortalin in Parkinson's disease: functional impact of disease-related variants on mitochondrial homeostasis","volume":"19","author":"Burbulla","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mcn.2012.11.011_bb0110","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1073\/pnas.0605208103","article-title":"Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons","volume":"104","author":"Ekstrand","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcn.2012.11.011_bb0115","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1111\/j.1471-4159.2006.03990.x","article-title":"The role of mitochondria in inherited neurodegenerative diseases","volume":"97","author":"Kwong","year":"2006","journal-title":"J. Neurochem."},{"key":"10.1016\/j.mcn.2012.11.011_bb0120","series-title":"Human molecular genetics 16 Spec No. 2:R183-194","article-title":"Parkinson's disease","author":"Thomas","year":"2007"},{"key":"10.1016\/j.mcn.2012.11.011_bb0125","doi-asserted-by":"crossref","first-page":"9089","DOI":"10.1074\/jbc.M710012200","article-title":"Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain","volume":"283","author":"Devi","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mcn.2012.11.011_bb0130","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1074\/mcp.M700467-MCP200","article-title":"Quantitative proteomics of a presymptomatic A53T alpha-synuclein Drosophila model of Parkinson disease","volume":"7","author":"Xun","year":"2008","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.mcn.2012.11.011_bb0135","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0014-4886(03)00342-X","article-title":"Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP","volume":"186","author":"Song","year":"2004","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.mcn.2012.11.011_bb0140","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0002-9440(10)64553-1","article-title":"alpha-synuclein promotes mitochondrial deficit and oxidative stress","volume":"157","author":"Hsu","year":"2000","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.mcn.2012.11.011_bb0145","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.nbd.2005.08.018","article-title":"Mice lacking alpha-synuclein are resistant to mitochondrial toxins","volume":"21","author":"Klivenyi","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.mcn.2012.11.011_bb0150","doi-asserted-by":"crossref","first-page":"14524","DOI":"10.1073\/pnas.172514599","article-title":"Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP","volume":"99","author":"Dauer","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcn.2012.11.011_bb0155","doi-asserted-by":"crossref","first-page":"18614","DOI":"10.1074\/jbc.M401135200","article-title":"Mitochondrial dysfunction and oxidative damage in parkin-deficient mice","volume":"279","author":"Palacino","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mcn.2012.11.011_bb0160","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/j.1471-4159.2006.03777.x","article-title":"Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline","volume":"97","author":"Casarejos","year":"2006","journal-title":"J. Neurochem."},{"key":"10.1016\/j.mcn.2012.11.011_bb0165","doi-asserted-by":"crossref","first-page":"e4597","DOI":"10.1371\/journal.pone.0004597","article-title":"PINK1 defect causes mitochondrial dysfunction, proteasomal deficit and alpha-synuclein aggregation in cell culture models of Parkinson's disease","volume":"4","author":"Liu","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.mcn.2012.11.011_bb0170","doi-asserted-by":"crossref","first-page":"e5777","DOI":"10.1371\/journal.pone.0005777","article-title":"Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration","volume":"4","author":"Gispert","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.mcn.2012.11.011_bb0175","doi-asserted-by":"crossref","first-page":"11364","DOI":"10.1073\/pnas.0802076105","article-title":"Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress","volume":"105","author":"Gautier","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcn.2012.11.011_bb0180","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1093\/hmg\/ddq288","article-title":"Loss of the Parkinson's disease-linked gene DJ-1 perturbs mitochondrial dynamics","volume":"19","author":"Irrcher","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mcn.2012.11.011_bb0185","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.gene.2007.06.013","article-title":"Drosophila DJ-1 mutants are sensitive to oxidative stress and show reduced lifespan and motor deficits","volume":"400","author":"Lavara-Culebras","year":"2007","journal-title":"Gene"},{"key":"10.1016\/j.mcn.2012.11.011_bb0190","doi-asserted-by":"crossref","first-page":"e9367","DOI":"10.1371\/journal.pone.0009367","article-title":"Reduced basal autophagy and impaired mitochondrial dynamics due to loss of Parkinson's disease-associated protein DJ-1","volume":"5","author":"Krebiehl","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.mcn.2012.11.011_bb0195","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.stem.2011.01.013","article-title":"LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress","volume":"8","author":"Nguyen","year":"2011","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.mcn.2012.11.011_bb0200","doi-asserted-by":"crossref","first-page":"9210","DOI":"10.1523\/JNEUROSCI.2281-09.2009","article-title":"LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans","volume":"29","author":"Saha","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.mcn.2012.11.011_bb0205","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1093\/hmg\/dds003","article-title":"LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1","volume":"21","author":"Wang","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mcn.2012.11.011_bb0210","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1023\/B:NERE.0000014824.04728.dd","article-title":"The energetics of Huntington's disease","volume":"29","author":"Browne","year":"2004","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.mcn.2012.11.011_bb0215","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/1531-8249(200001)47:1<64::AID-ANA11>3.0.CO;2-S","article-title":"Higher sedentary energy expenditure in patients with Huntington's disease","volume":"47","author":"Pratley","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.mcn.2012.11.011_bb0220","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.expneurol.2007.12.026","article-title":"The metabolic profile of early Huntington's disease \u2014 a combined human and transgenic mouse study","volume":"210","author":"Goodman","year":"2008","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.mcn.2012.11.011_bb0225","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1212\/01.WNL.0000031791.10922.CF","article-title":"Weight loss in early stage of Huntington's disease","volume":"59","author":"Djousse","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.mcn.2012.11.011_bb0230","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/archneur.1992.00530350075022","article-title":"Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease","volume":"49","author":"Grafton","year":"1992","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.mcn.2012.11.011_bb0235","first-page":"1591","article-title":"Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study","volume":"42","author":"Feigin","year":"2001","journal-title":"J. Nucl. Med."},{"issue":"Pt 6","key":"10.1016\/j.mcn.2012.11.011_bb0240","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/brain\/119.6.2085","article-title":"Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease","volume":"119","author":"Antonini","year":"1996","journal-title":"Brain"},{"key":"10.1016\/j.mcn.2012.11.011_bb0245","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF00870669","article-title":"Striatal glucose consumption in chorea-free subjects at risk of Huntington's disease","volume":"241","author":"Kuwert","year":"1993","journal-title":"J. Neurol."},{"key":"10.1016\/j.mcn.2012.11.011_bb0250","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1212\/WNL.43.12.2689","article-title":"Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy","volume":"43","author":"Jenkins","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.mcn.2012.11.011_bb0255","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/ana.410410206","article-title":"Energy metabolism defects in Huntington's disease and effects of coenzyme Q10","volume":"41","author":"Koroshetz","year":"1997","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.mcn.2012.11.011_bb0260","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/1531-8249(200007)48:1<72::AID-ANA11>3.0.CO;2-I","article-title":"Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy","volume":"48","author":"Lodi","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.mcn.2012.11.011_bb0265","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/mds.20373","article-title":"Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease","volume":"20","author":"Saft","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.mcn.2012.11.011_bb0270","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/ana.410410514","article-title":"Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia","volume":"41","author":"Browne","year":"1997","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.mcn.2012.11.011_bb0275","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/ana.410390317","article-title":"Mitochondrial defect in Huntington's disease caudate nucleus","volume":"39","author":"Gu","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.mcn.2012.11.011_bb0280","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/1531-8249(199901)45:1<25::AID-ART6>3.0.CO;2-E","article-title":"Biochemical abnormalities and excitotoxicity in Huntington's disease brain","volume":"45","author":"Tabrizi","year":"1999","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.mcn.2012.11.011_bb0285","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1093\/hmg\/ddi319","article-title":"HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism","volume":"14","author":"Seong","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mcn.2012.11.011_bb0290","doi-asserted-by":"crossref","first-page":"30773","DOI":"10.1074\/jbc.M504749200","article-title":"Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin","volume":"280","author":"Milakovic","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mcn.2012.11.011_bb0295","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/j.1471-4159.1993.tb03633.x","article-title":"Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate","volume":"61","author":"Beal","year":"1993","journal-title":"J. Neurochem."},{"key":"10.1016\/j.mcn.2012.11.011_bb0300","doi-asserted-by":"crossref","first-page":"7105","DOI":"10.1073\/pnas.92.15.7105","article-title":"Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates","volume":"92","author":"Brouillet","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcn.2012.11.011_bb0305","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1017\/S0317167100032212","article-title":"3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin","volume":"18","author":"Ludolph","year":"1991","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.mcn.2012.11.011_bb0310","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1471-4159.1993.tb05859.x","article-title":"Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid","volume":"60","author":"Brouillet","year":"1993","journal-title":"J. Neurochem."},{"key":"10.1016\/j.mcn.2012.11.011_bb0315","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s10571-007-9206-5","article-title":"Huntington's disease and mitochondrial DNA deletions: event or regular mechanism for mutant huntingtin protein and CAG repeats expansion?!","volume":"27","author":"Banoei","year":"2007","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.mcn.2012.11.011_bb0320","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.bbrc.2007.05.093","article-title":"Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington's disease patients","volume":"359","author":"Chen","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.mcn.2012.11.011_bb0325","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1212\/WNL.45.10.1879","article-title":"Marked increase in mitochondrial DNA deletion levels in the cerebral cortex of Huntington's disease patients","volume":"45","author":"Horton","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.mcn.2012.11.011_bb0330","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00109-010-0589-2","article-title":"Mitochondrial haplogroup H correlates with ATP levels and age at onset in Huntington disease","volume":"88","author":"Arning","year":"2010","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.mcn.2012.11.011_bb0335","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.dnarep.2008.09.004","article-title":"Mitochondrial DNA damage is a hallmark of chemically induced and the R6\/2 transgenic model of Huntington's disease","volume":"8","author":"Acevedo-Torres","year":"2009","journal-title":"DNA Repair (Amst.)"},{"key":"10.1016\/j.mcn.2012.11.011_bb0340","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.expneurol.2010.01.002","article-title":"Mitochondrial-dependent apoptosis in Huntington's disease human cybrids","volume":"222","author":"Ferreira","year":"2010","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.mcn.2012.11.011_bb0345","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1471-4159.2006.04361.x","article-title":"Mitochondrial dysfunction in Huntington's disease: the bioenergetics of isolated and in situ mitochondria from transgenic mice","volume":"101","author":"Oliveira","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.mcn.2012.11.011_bb0350","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1172\/JCI45691","article-title":"Energy deficit in Huntington disease: why it matters","volume":"121","author":"Mochel","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.mcn.2012.11.011_bb0355","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/hmg\/ddh162","article-title":"Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release","volume":"13","author":"Choo","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mcn.2012.11.011_bb0360","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/cne.21272","article-title":"Cellular and subcellular localization of Huntingtin [corrected] aggregates in the brain of a rat transgenic for Huntington disease","volume":"501","author":"Petrasch-Parwez","year":"2007","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.mcn.2012.11.011_bb0365","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nn884","article-title":"Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines","volume":"5","author":"Panov","year":"2002","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.mcn.2012.11.011_bb0370","doi-asserted-by":"crossref","first-page":"8195","DOI":"10.1128\/MCB.24.18.8195-8209.2004","article-title":"Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro","volume":"24","author":"Trushina","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.mcn.2012.11.011_bb0375","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1523\/JNEUROSCI.0106-08.2008","article-title":"N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking","volume":"28","author":"Orr","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.mcn.2012.11.011_bb0380","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.brainresrev.2009.04.001","article-title":"Mitochondrial structural and functional dynamics in Huntington's disease","volume":"61","author":"Reddy","year":"2009","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.mcn.2012.11.011_bb0385","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.nbd.2005.12.007","article-title":"Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons","volume":"22","author":"Chang","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.mcn.2012.11.011_bb0390","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1093\/hmg\/ddq306","article-title":"Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease","volume":"19","author":"Kim","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mcn.2012.11.011_bb0395","doi-asserted-by":"crossref","DOI":"10.1093\/hmg\/ddr024","article-title":"Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage","author":"Shirendeb","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mcn.2012.11.011_bb0400","doi-asserted-by":"crossref","DOI":"10.1038\/nm.2313","article-title":"Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity","author":"Song","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.mcn.2012.11.011_bb0405","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/hmg\/ddn404","article-title":"Effects of overexpression of huntingtin proteins on mitochondrial integrity","volume":"18","author":"Wang","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mcn.2012.11.011_bb0410","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nm0311-245","article-title":"Hugging tight in Huntington's","volume":"17","author":"Johri","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.mcn.2012.11.011_bb0415","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/emmm.201000102","article-title":"Mitochondrial fission and cristae disruption increase the response of cell models of Huntington's disease to apoptotic stimuli","volume":"2","author":"Costa","year":"2010","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.mcn.2012.11.011_bb0420","article-title":"Light and electron microscopic characterization of the evolution of cellular pathology in the Hdh((CAG)150) Huntington's disease knock-in mouse","author":"Bayram-Weston","year":"2011","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.mcn.2012.11.011_bb0425","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00702-009-0328-4","article-title":"Abnormal morphology of peripheral cell tissues from patients with Huntington disease","volume":"117","author":"Squitieri","year":"2010","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.mcn.2012.11.011_bb0430","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11010-005-3454-9","article-title":"Ca2+-induced permeability transition in human lymphoblastoid cell mitochondria from normal and Huntington's disease individuals","volume":"269","author":"Panov","year":"2005","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.mcn.2012.11.011_bb0435","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/ana.20754","article-title":"Low stability of Huntington muscle mitochondria against Ca2+ in R6\/2 mice","volume":"59","author":"Gizatullina","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.mcn.2012.11.011_bb0440","doi-asserted-by":"crossref","first-page":"30715","DOI":"10.1074\/jbc.M709555200","article-title":"Impaired regulation of brain mitochondria by extramitochondrial Ca2+ in transgenic Huntington disease rats","volume":"283","author":"Gellerich","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mcn.2012.11.011_bb0445","doi-asserted-by":"crossref","first-page":"34785","DOI":"10.1074\/jbc.M603845200","article-title":"Mutant huntingtin expression induces mitochondrial calcium handling defects in clonal striatal cells: functional consequences","volume":"281","author":"Milakovic","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mcn.2012.11.011_bb0450","doi-asserted-by":"crossref","first-page":"5780","DOI":"10.1074\/jbc.M704704200","article-title":"Calcium homeostasis and mitochondrial dysfunction in striatal neurons of Huntington disease","volume":"283","author":"Lim","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mcn.2012.11.011_bb0455","doi-asserted-by":"crossref","first-page":"11174","DOI":"10.1523\/JNEUROSCI.3004-06.2006","article-title":"Mitochondrial-dependent Ca2+ handling in Huntington's disease striatal cells: effect of histone deacetylase inhibitors","volume":"26","author":"Oliveira","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.mcn.2012.11.011_bb0460","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0168-9525(03)00074-X","article-title":"Transcriptional abnormalities in Huntington disease","volume":"19","author":"Sugars","year":"2003","journal-title":"Trends Genet."},{"key":"10.1016\/j.mcn.2012.11.011_bb0465","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.pneurobio.2007.03.004","article-title":"Transcriptional signatures in Huntington's disease","volume":"83","author":"Cha","year":"2007","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.mcn.2012.11.011_bb0470","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.1073\/pnas.100110097","article-title":"The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription","volume":"97","author":"Steffan","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcn.2012.11.011_bb0475","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1126\/science.1056784","article-title":"Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity","volume":"291","author":"Nucifora","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.mcn.2012.11.011_bb0480","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.nbd.2005.11.001","article-title":"Decreased association of the transcription factor Sp1 with genes downregulated in Huntington's disease","volume":"22","author":"Chen-Plotkin","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.mcn.2012.11.011_bb0485","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1126\/science.1072613","article-title":"Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease","volume":"296","author":"Dunah","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.mcn.2012.11.011_bb0490","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.mcn.2005.05.003","article-title":"Mutant huntingtin represses CBP, but not p300, by binding and protein degradation","volume":"30","author":"Cong","year":"2005","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.mcn.2012.11.011_bb0495","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1074\/jbc.M310226200","article-title":"Decreased cAMP response element-mediated transcription: an early event in exon 1 and full-length cell models of Huntington's disease that contributes to polyglutamine pathogenesis","volume":"279","author":"Sugars","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mcn.2012.11.011_bb0500","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1093\/hmg\/ddp243","article-title":"Impaired PGC-1alpha function in muscle in Huntington's disease","volume":"18","author":"Chaturvedi","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mcn.2012.11.011_bb0505","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1093\/hmg\/ddq229","article-title":"Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation","volume":"19","author":"Chaturvedi","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mcn.2012.11.011_bb0510","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.neuron.2005.06.005","article-title":"p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease","volume":"47","author":"Bae","year":"2005","journal-title":"Neuron"},{"key":"10.1016\/j.mcn.2012.11.011_bb0515","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cell.2006.09.015","article-title":"Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration","volume":"127","author":"Cui","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.mcn.2012.11.011_bb0520","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cmet.2005.05.004","article-title":"Metabolic control through the PGC-1 family of transcription coactivators","volume":"1","author":"Lin","year":"2005","journal-title":"Cell Metab."},{"key":"10.1016\/j.mcn.2012.11.011_bb0525","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1471-4159.2008.05388.x","article-title":"PPAR: a therapeutic target in Parkinson's disease","volume":"106","author":"Chaturvedi","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.mcn.2012.11.011_bb0530","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.cmet.2006.10.004","article-title":"Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration","volume":"4","author":"Weydt","year":"2006","journal-title":"Cell Metab."},{"key":"10.1016\/j.mcn.2012.11.011_bb0535","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.cell.2006.10.023","article-title":"PGC-1alpha, a new therapeutic target in Huntington's disease?","volume":"127","author":"McGill","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.mcn.2012.11.011_bb0540","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1093\/hmg\/ddp243","article-title":"Impaired PGC-1alpha function in muscle in Huntington's disease","volume":"18","author":"Chaturvedi","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mcn.2012.11.011_bb0545","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2006.09.024","article-title":"Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators","volume":"127","author":"St-Pierre","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.mcn.2012.11.011_bb0550","doi-asserted-by":"crossref","DOI":"10.1093\/hmg\/dds178","article-title":"Transducer of regulated CREB-binding proteins (TORCs) transcription and function is impaired in Huntington's disease","author":"Chaturvedi","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mcn.2012.11.011_bb0555","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s00726-011-0851-0","article-title":"Neuroprotective effects of creatine","volume":"40","author":"Beal","year":"2011","journal-title":"Amino Acids"},{"key":"10.1016\/j.mcn.2012.11.011_bb0560","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s12017-008-8053-y","article-title":"Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases","volume":"10","author":"Adhihetty","year":"2008","journal-title":"Neuromolecular Med"},{"key":"10.1016\/j.mcn.2012.11.011_bb0565","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1006\/exnr.1999.7049","article-title":"Creatine and cyclocreatine attenuate MPTP neurotoxicity","volume":"157","author":"Matthews","year":"1999","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.mcn.2012.11.011_bb0570","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1385\/JMN:21:3:191","article-title":"Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease","volume":"21","author":"Klivenyi","year":"2003","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.mcn.2012.11.011_bb0575","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1006\/nbdi.2001.0406","article-title":"Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease","volume":"8","author":"Andreassen","year":"2001","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.mcn.2012.11.011_bb0580","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1046\/j.1471-4159.2003.01706.x","article-title":"Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice","volume":"85","author":"Dedeoglu","year":"2003","journal-title":"J. Neurochem."},{"key":"10.1016\/j.mcn.2012.11.011_bb0585","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1523\/JNEUROSCI.20-12-04389.2000","article-title":"Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease","volume":"20","author":"Ferrante","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.mcn.2012.11.011_bb0590","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1111\/j.1471-4159.2009.06074.x","article-title":"Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases","volume":"109","author":"Yang","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.mcn.2012.11.011_bb0595","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1212\/01.wnl.0000238518.34389.12","article-title":"Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial","volume":"67","author":"Bender","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.mcn.2012.11.011_bb0600","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.nutres.2008.01.001","article-title":"Long-term creatine supplementation is safe in aged patients with Parkinson disease","volume":"28","author":"Bender","year":"2008","journal-title":"Nutr. Res."},{"key":"10.1016\/j.mcn.2012.11.011_bb0605","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/1545968306293449","article-title":"Resistance training with creatine monohydrate improves upper-body strength in patients with Parkinson disease: a randomized trial","volume":"21","author":"Hass","year":"2007","journal-title":"Neurorehabil. Neural Repair"},{"key":"10.1016\/j.mcn.2012.11.011_bb0610","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1212\/01.wnl.0000201252.57661.e1","article-title":"A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease","volume":"66","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.mcn.2012.11.011_bb0615","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/WNF.0b013e3181342f32","article-title":"A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results","volume":"31","author":"Investigators","year":"2008","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.mcn.2012.11.011_bb0620","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1126\/science.315.5820.1778","article-title":"Clinical research. Testing a novel strategy against Parkinson's disease","volume":"315","author":"Couzin","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.mcn.2012.11.011_bb0625","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/01.wnl.0000194318.74946.b6","article-title":"Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG","volume":"66","author":"Hersch","year":"2006","journal-title":"Neurology"},{"issue":"Suppl. 3","key":"10.1016\/j.mcn.2012.11.011_bb0630","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1002\/ana.10479","article-title":"Bioenergetic approaches for neuroprotection in Parkinson's disease","volume":"53","author":"Beal","year":"2003","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.mcn.2012.11.011_bb0635","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0014-4886(95)90033-0","article-title":"Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity","volume":"132","author":"Schulz","year":"1995","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.mcn.2012.11.011_bb0640","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0006-8993(97)01192-X","article-title":"Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3, tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice","volume":"783","author":"Beal","year":"1998","journal-title":"Brain Res."},{"key":"10.1016\/j.mcn.2012.11.011_bb0645","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1111\/j.1471-4159.2007.05097.x","article-title":"Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism","volume":"104","author":"Cleren","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.mcn.2012.11.011_bb0650","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.bbadis.2006.03.004","article-title":"Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice","volume":"1762","author":"Smith","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.mcn.2012.11.011_bb0655","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1523\/JNEUROSCI.22-05-01592.2002","article-title":"Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease","volume":"22","author":"Ferrante","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.mcn.2012.11.011_bb0660","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.bbadis.2005.11.002","article-title":"Combination therapy using minocycline and coenzyme Q10 in R6\/2 transgenic Huntington's disease mice","volume":"1762","author":"Stack","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.mcn.2012.11.011_bb0665","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3940(01)02326-6","article-title":"Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model","volume":"315","author":"Schilling","year":"2001","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.mcn.2012.11.011_bb0670","first-page":"597","article-title":"Coenzyme Q10 effects in neurodegenerative disease","volume":"5","author":"Spindler","year":"2009","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.mcn.2012.11.011_bb0675","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1212\/WNL.57.3.397","article-title":"A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease","volume":"57","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.mcn.2012.11.011_bb0680","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1212\/WNL.50.3.793","article-title":"Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients","volume":"50","author":"Shults","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.mcn.2012.11.011_bb0685","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/archneur.59.10.1541","article-title":"Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline","volume":"59","author":"Shults","year":"2002","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.mcn.2012.11.011_bb0690","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0304-3940(03)00185-X","article-title":"Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease","volume":"341","author":"Muller","year":"2003","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.mcn.2012.11.011_bb0695","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1001\/archneur.60.8.1170-b","article-title":"The effect of coenzyme Q10 therapy in Parkinson disease could be symptomatic","volume":"60","author":"Horstink","year":"2003","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.mcn.2012.11.011_bb0700","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1007\/s00115-007-2285-1","article-title":"Coenzyme Q10 in Parkinson's disease. Symptomatic or neuroprotective effects?","volume":"78","author":"Storch","year":"2007","journal-title":"Nervenarzt"},{"key":"10.1016\/j.mcn.2012.11.011_bb0705","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/archneur.64.7.nct60005","article-title":"Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease","volume":"64","author":"Storch","year":"2007","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.mcn.2012.11.011_bb0710","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.expneurol.2004.05.003","article-title":"Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease","volume":"188","author":"Shults","year":"2004","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.mcn.2012.11.011_bb0715","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1212\/01.wnl.0000250355.28474.8e","article-title":"A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease","volume":"68","author":"NINDS-NETPD","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.mcn.2012.11.011_bb0720","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.pneurobio.2011.10.004","article-title":"PGC-1alpha at the intersection of bioenergetics regulation and neuron function: From Huntington's disease to Parkinson's disease and beyond","volume":"97","author":"Tsunemi","year":"2012","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.mcn.2012.11.011_bb0725","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/hmg\/ddn428","article-title":"Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse models","volume":"18","author":"Phan","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mcn.2012.11.011_bb0730","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.cell.2011.02.010","article-title":"PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease","volume":"144","author":"Shin","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.mcn.2012.11.011_bb0735","doi-asserted-by":"crossref","first-page":"52ra73","DOI":"10.1126\/scitranslmed.3001059","article-title":"PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease","volume":"2","author":"Zheng","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.mcn.2012.11.011_bb0740","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.molcel.2003.08.013","article-title":"TORCs: transducers of regulated CREB activity","volume":"12","author":"Conkright","year":"2003","journal-title":"Mol. Cell"},{"key":"10.1016\/j.mcn.2012.11.011_bb0745","doi-asserted-by":"crossref","first-page":"14379","DOI":"10.1073\/pnas.0606714103","article-title":"Transducer of regulated CREB-binding proteins (TORCs) induce PGC-1alpha transcription and mitochondrial biogenesis in muscle cells","volume":"103","author":"Wu","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcn.2012.11.011_bb0750","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/hmg\/ddr541","article-title":"Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease","volume":"21","author":"Johri","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mcn.2012.11.011_bb0755","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.nbd.2011.08.016","article-title":"PPARgamma rescue of the mitochondrial dysfunction in Huntington's disease","volume":"45","author":"Chiang","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.mcn.2012.11.011_bb0760","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1073\/pnas.0800979105","article-title":"Gene expression-based screening identifies microtubule inhibitors as inducers of PGC-1alpha and oxidative phosphorylation","volume":"105","author":"Arany","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcn.2012.11.011_bb0765","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2012.05.019","article-title":"Activating mitochondrial regulator PGC-1alpha expression by astrocytic NGF is a therapeutic strategy for Huntington's disease","author":"Chen","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.mcn.2012.11.011_bb0770","doi-asserted-by":"crossref","first-page":"37948","DOI":"10.1074\/jbc.M305204200","article-title":"NF-E2-related factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons","volume":"278","author":"Lee","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mcn.2012.11.011_bb0775","doi-asserted-by":"crossref","first-page":"22925","DOI":"10.1074\/jbc.M414635200","article-title":"Induction of the Nrf2-driven antioxidant response confers neuroprotection during mitochondrial stress in vivo","volume":"280","author":"Shih","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mcn.2012.11.011_bb0780","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1089\/ars.2009.2445","article-title":"Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity","volume":"11","author":"Yang","year":"2009","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.mcn.2012.11.011_bb0785","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.freeradbiomed.2010.03.017","article-title":"Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease","volume":"49","author":"Stack","year":"2010","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.mcn.2012.11.011_bb0790","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1126\/science.1143780","article-title":"Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease","volume":"317","author":"Outeiro","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.mcn.2012.11.011_bb0795","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/00008877-200609000-00014","article-title":"Effect of resveratrol on 3-nitropropionic acid-induced biochemical and behavioural changes: possible neuroprotective mechanisms","volume":"17","author":"Kumar","year":"2006","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.mcn.2012.11.011_bb0800","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2006.11.013","article-title":"Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha","volume":"127","author":"Lagouge","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.mcn.2012.11.011_bb0805","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.expneurol.2010.05.006","article-title":"Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease","volume":"225","author":"Ho","year":"2010","journal-title":"Exp. Neurol."},{"issue":"5","key":"10.1016\/j.mcn.2012.11.011_bb0810","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.celrep.2012.10.001","article-title":"Targeting of XJB-5-131 to mitochondria suppresses oxidative DNA damage and motor decline in a mouse model of Huntington's disease","volume":"2","author":"Xun","year":"2012","journal-title":"Cell Rep."},{"key":"10.1016\/j.mcn.2012.11.011_bb0815","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/hmg\/ddh082","article-title":"Striatal cells from mutant huntingtin knock-in mice are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a non-apoptotic pathway","volume":"13","author":"Ruan","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mcn.2012.11.011_bb0820","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nm.2313","article-title":"Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity","volume":"17","author":"Song","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.mcn.2012.11.011_bb0825","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/hmg\/ddr475","article-title":"Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease","volume":"21","author":"Shirendeb","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mcn.2012.11.011_bb0830","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1093\/hmg\/ddr024","article-title":"Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage","volume":"20","author":"Shirendeb","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mcn.2012.11.011_bb0835","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.cell.2005.10.030","article-title":"In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets","volume":"123","author":"Zhai","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.mcn.2012.11.011_bb0840","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1093\/hmg\/dds178","article-title":"Transducer of regulated CREB-binding proteins (TORCs) transcription and function is impaired in Huntington's disease","volume":"21","author":"Chaturvedi","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mcn.2012.11.011_bb0845","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.bbadis.2011.03.007","article-title":"PARK6 PINK1 mutants are defective in maintaining mitochondrial membrane potential and inhibiting ROS formation of substantia nigra dopaminergic neurons","volume":"1812","author":"Wang","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.mcn.2012.11.011_bb0850","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.nbd.2007.07.010","article-title":"PINK1 mutants associated with recessive Parkinson's disease are defective in inhibiting mitochondrial release of cytochrome c","volume":"28","author":"Wang","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.mcn.2012.11.011_bb0855","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/ncomms2016","article-title":"PINK1 autophosphorylation upon membrane potential dissipation is essential for Parkin recruitment to damaged mitochondria","volume":"3","author":"Okatsu","year":"2012","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mcn.2012.11.011_bb0860","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1083\/jcb.200910140","article-title":"PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy","volume":"189","author":"Matsuda","year":"2010","journal-title":"J. Cell. Biol."},{"key":"10.1016\/j.mcn.2012.11.011_bb0865","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1073\/pnas.0911187107","article-title":"PINK1-dependent recruitment of Parkin to mitochondria in mitophagy","volume":"107","author":"Vives-Bauza","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcn.2012.11.011_bb0870","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1111\/j.1471-4159.2009.05932.x","article-title":"Mutant Pink1 induces mitochondrial dysfunction in a neuronal cell model of Parkinson's disease by disturbing calcium flux","volume":"108","author":"Marongiu","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.mcn.2012.11.011_bb0875","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/brain\/awl114","article-title":"PINK1 protein in normal human brain and Parkinson's disease","volume":"129","author":"Gandhi","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.mcn.2012.11.011_bb0880","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1093\/hmg\/ddi377","article-title":"Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism","volume":"14","author":"Silvestri","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mcn.2012.11.011_bb0885","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1073\/pnas.0705363105","article-title":"Cytoplasmic Pink1 activity protects neurons from dopaminergic neurotoxin MPTP","volume":"105","author":"Haque","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcn.2012.11.011_bb0890","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.cell.2011.10.018","article-title":"PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility","volume":"147","author":"Wang","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.mcn.2012.11.011_bb0895","doi-asserted-by":"crossref","first-page":"e1002537","DOI":"10.1371\/journal.pgen.1002537","article-title":"Parkinson's disease-associated kinase PINK1 regulates Miro protein level and axonal transport of mitochondria","volume":"8","author":"Liu","year":"2012","journal-title":"PLoS Genet."},{"key":"10.1016\/j.mcn.2012.11.011_bb0900","doi-asserted-by":"crossref","first-page":"10814","DOI":"10.1074\/jbc.M110.132514","article-title":"Mutant A53T alpha-synuclein induces neuronal death by increasing mitochondrial autophagy","volume":"286","author":"Choubey","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mcn.2012.11.011_bb0905","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.neulet.2010.09.061","article-title":"Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo","volume":"486","author":"Chinta","year":"2010","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.mcn.2012.11.011_bb0910","doi-asserted-by":"crossref","DOI":"10.1111\/j.1471-4159.2012.07769.x","article-title":"Alpha-synuclein impairs normal dynamics of mitochondria in cell and animal models of Parkinson's disease","author":"Xie","year":"2012","journal-title":"J. Neurochem."},{"key":"10.1016\/j.mcn.2012.11.011_bb0915","doi-asserted-by":"crossref","first-page":"20710","DOI":"10.1074\/jbc.M110.213538","article-title":"Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein","volume":"286","author":"Nakamura","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mcn.2012.11.011_bb0920","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/hmg\/ddq430","article-title":"DJ-1 acts in parallel to the PINK1\/parkin pathway to control mitochondrial function and autophagy","volume":"20","author":"Thomas","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mcn.2012.11.011_bb0925","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1073\/pnas.0501282102","article-title":"Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress","volume":"102","author":"Kim","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcn.2012.11.011_bb0930","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1093\/hmg\/ddm249","article-title":"Paraquat induces dopaminergic dysfunction and proteasome impairment in DJ-1-deficient mice","volume":"16","author":"Yang","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mcn.2012.11.011_bb0935","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/j.1471-4159.2012.07734.x","article-title":"Parkinson's disease-associated DJ-1 mutations impair mitochondrial dynamics and cause mitochondrial dysfunction","volume":"121","author":"Wang","year":"2012","journal-title":"J. Neurochem."},{"key":"10.1016\/j.mcn.2012.11.011_bb0940","doi-asserted-by":"crossref","first-page":"e32629","DOI":"10.1371\/journal.pone.0032629","article-title":"DJ-1 null dopaminergic neuronal cells exhibit defects in mitochondrial function and structure: involvement of mitochondrial complex I assembly","volume":"7","author":"Heo","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.mcn.2012.11.011_bb0945","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.bbrc.2009.10.025","article-title":"DJ-1 binds to mitochondrial complex I and maintains its activity","volume":"390","author":"Hayashi","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.mcn.2012.11.011_bb0950","doi-asserted-by":"crossref","first-page":"706","DOI":"10.4161\/auto.5.5.8505","article-title":"Parkin-induced mitophagy in the pathogenesis of Parkinson disease","volume":"5","author":"Narendra","year":"2009","journal-title":"Autophagy"},{"key":"10.1016\/j.mcn.2012.11.011_bb0955","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1083\/jcb.201001039","article-title":"Disease-causing mutations in parkin impair mitochondrial ubiquitination, aggregation, and HDAC6-dependent mitophagy","volume":"189","author":"Lee","year":"2010","journal-title":"J. Cell. Biol."},{"key":"10.1016\/j.mcn.2012.11.011_bb0960","doi-asserted-by":"crossref","first-page":"11649","DOI":"10.1074\/jbc.M110.144238","article-title":"Parkin ubiquitinates Drp1 for proteasome-dependent degradation: implication of dysregulated mitochondrial dynamics in Parkinson disease","volume":"286","author":"Wang","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mcn.2012.11.011_bb0965","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/hmg\/ddr235","article-title":"The PINK1\/Parkin pathway regulates mitochondrial dynamics and function in mammalian hippocampal and dopaminergic neurons","volume":"20","author":"Yu","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mcn.2012.11.011_bb0970","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e3181ff9685","article-title":"Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2","volume":"75","author":"Mortiboys","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.mcn.2012.11.011_bb0975","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/j.1471-4159.2012.07809.x","article-title":"Leucine-rich repeat kinase 2 disturbs mitochondrial dynamics via Dynamin-like protein","volume":"122","author":"Niu","year":"2012","journal-title":"J. Neurochem."},{"key":"10.1016\/j.mcn.2012.11.011_bb0980","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/WNF.0b013e3181342f32","article-title":"A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results","volume":"31","author":"Investigators., N. N.-P.","year":"2008","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.mcn.2012.11.011_bb0985","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/mds.25175","article-title":"Design innovations and baseline findings in a long-term Parkinson's trial: the national institute of neurological disorders and stroke exploratory trials in Parkinson's Disease Long-Term Study-1","volume":"27","author":"Elm","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.mcn.2012.11.011_bb0990","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1212\/01.wnl.0000250355.28474.8e","article-title":"A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease","volume":"68","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.mcn.2012.11.011_bb0995","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1212\/01.WNL.0000090629.40891.4B","article-title":"Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial","volume":"61","author":"Verbessem","year":"2003","journal-title":"Neurology"}],"container-title":["Molecular and Cellular Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044743112002102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044743112002102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T12:47:52Z","timestamp":1562417272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044743112002102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":199,"alternative-id":["S1044743112002102"],"URL":"https:\/\/doi.org\/10.1016\/j.mcn.2012.11.011","relation":{},"ISSN":["1044-7431"],"issn-type":[{"value":"1044-7431","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}